standard of care in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1.56 [0.45; 5.47]
1.56 [0.45 ; 5.47 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1 0% 345 NA not evaluable deaths (time to event analysis only)detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1.56 [0.45; 5.47]
1.56 [0.45 ; 5.47 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1 0% 345 NA not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1.01 [0.58; 1.76]
1.01 [0.58 ; 1.76 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1 0% 444 NA not evaluable clinical improvementdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1.23 [0.82; 1.86]
1.23 [0.82 ; 1.86 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1 0% 444 NA not evaluable clinical improvement (14-day)detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 0.99 [0.57; 1.72]
0.99 [0.57 ; 1.72 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1 0% 444 NA not evaluable mechanical ventilationdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 0.56 [0.26; 1.23]
0.56 [0.26 ; 1.23 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1 0% 345 NA not evaluable serious adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 0.53 [0.10; 2.79]
0.53 [0.10 ; 2.79 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1 0% 416 NA not evaluable acute kidney injury detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 0.85 [0.31; 2.29]
0.85 [0.31 ; 2.29 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1 0% 345 NA not evaluable adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 0.45 [0.29; 0.70]
0.45 [0.29 ; 0.70 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1 0% 416 NA not evaluable arrhythmiadetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 0.45 [0.05; 4.33]
0.45 [0.05 ; 4.33 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1 0% 416 NA not evaluable elevated liver enzymesdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 0.29 [0.12; 0.71]
0.29 [0.12 ; 0.71 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1 0% 416 NA not evaluable long QTdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 0.10 [0.01; 0.79]
0.10 [0.01 ; 0.79 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1 0% 174 NA not evaluable Thromboembolic eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1.12 [0.39; 3.22]
1.12 [0.39 ; 3.22 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (REV) 1 0% 345 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-11 15:23 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 651
- roots T: 651
